Scientific evidence on chondroprotective drugs by Llisterri Giménez, Mar & Universitat Autònoma de Barcelona. Facultat de Veterinària
SCIENTIFIC EVIDENCE ON
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Most joint diseases are characterized by inflammation,
pain, functional disability and joint deformity with
remodelling of the subchondral bone, and the only non-
surgical treatment that modifies the disease is
chondroprotective drugs.
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• Dysplasia and osteoarthritis 
incidence reduction
• Pain relief
• Functional improvement
• Protective effect on joint cartilage
DOG
• Better quality of life
• Pain relief
• Functional improvement
• Reduce the need for analgesics and 
surgery delay
HUMAN
• Cartilage protection
• Factors that promote degradation  
and inflammation are decreased
• Degenerative process is slowed 
down
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• It is a natural 
compound of 
glycosaminoglycan
• It is the major 
glycosaminoglycan 
found in the 
cartilage
• It is one of the 
main molecular 
components of 
joint fluid 
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I. Recommending, or not, chondroprotective drugs.
II. Assessing the effectiveness of the treatment with 
these compounds.
III. Evaluating its safety in the treatment.
IV. Estimating its bioavailability.
I. The treatment with chondroprotectors is 
recommended.
II. Current scientific evidence about its 
effectiveness is still weak and unclear. 
III. They are safe drugs even in chronic 
administrations. 
IV. The bioavailability 
is still controversial
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